Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer
Trial Results: The Phase 2 trial (Actuate-1801 Part 3B) demonstrated that the combination of elraglusib with gemcitabine/nab-paclitaxel significantly improved median overall survival and 1-year survival rates in previously untreated patients with metastatic pancreatic ductal adenocarcinoma compared to gemcitabine/nab-paclitaxel alone.
Upcoming Presentation: Actuate Therapeutics will present these findings at the ASCO annual meeting on May 31, 2025, and will host a KOL event to discuss the data further with key opinion leaders in oncology.
Trade with 70% Backtested Accuracy
Analyst Views on ACTU
About ACTU
About the author
Actuate Therapeutics Announces Encouraging Phase II Results for Salivary Gland Cancers
Positive Study Results: Actuate Therapeutics reported favorable outcomes from a Phase II study of elraglusib combined with carboplatin or cisplatin for advanced metastatic salivary gland cancers, showing a median overall survival of 18.6 months.
Patient Demographics and Survival Rates: The study included 47% adenoid cystic carcinoma (ACC) and 53% non-ACC patients, with non-ACC patients experiencing a median overall survival of 27.8 months.
Progression-Free Survival: The median progression-free survival was 6.4 months, with only 27% of patients remaining progression-free at one year, contrasting with historical estimates for ACC and non-ACC.
Market Reaction: Following the announcement, Actuate shares increased by over 4% in pre-market trading, closing at $7.52, reflecting a 1.35% rise from the previous day.
HC Wainwright & Co. Affirms Buy Rating for Actuate Therapeutics, Keeps $20 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
Actuate Therapeutics Reveals Pricing for $15.0 Million Public Stock Offering
Public Offering Announcement: Actuate Therapeutics, Inc. has priced an underwritten public offering of 2,142,858 shares of common stock at $7.00 per share, aiming to raise approximately $15 million for working capital and corporate purposes.
Use of Proceeds: The company plans to utilize the net proceeds from the offering for general corporate needs, with the offering expected to close on September 11, 2025, pending customary closing conditions.
Company Focus: Actuate Therapeutics is a clinical-stage biopharmaceutical company developing therapies for challenging cancers, with its lead drug, elraglusib, targeting pathways that promote tumor growth and resistance to conventional treatments.
Forward-Looking Statements: The press release includes forward-looking statements regarding the offering's timing and completion, emphasizing the inherent risks and uncertainties that could affect actual results.
Actuate Therapeutics Analyst Starts Coverage Positively; Check Out Tuesday's Top 3 Initiations
Analyst Ratings Updates: Top Wall Street analysts have revised their outlooks on several companies, with a focus on upgrades and new coverage initiations.
Actuate Therapeutics Coverage: B. Riley Securities analyst Mayank Mamtani initiated coverage on Actuate Therapeutics (ACTU) with a Buy rating and a price target of $20, while the stock closed at $7.98.
Gyre Therapeutics Coverage: HC Wainwright & Co. analyst Matthew Keller also initiated coverage on Gyre Therapeutics (GYRE) with a Buy rating and a price target of $18, closing at $8.18.
CareDx Coverage: William Blair analyst Andrew Brackmann started coverage on CareDx (CDNA) with a Market Perform rating, with shares closing at $12.75.
B. Riley Securities Begins Coverage of Actuate Therapeutics with a Buy Rating and Sets Price Target at $20
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing strategies and intelligence.
Market Winning Tool: Traders utilize Benzinga Pro's resources to enhance their trading success in the stock market.
Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer
Clinical Trial Announcement: Actuate Therapeutics has initiated a Phase 1b clinical trial at UPMC Hillman Cancer Center to evaluate the combination of elraglusib, retifanlimab, and modified FOLFIRINOX as a frontline therapy for advanced pancreatic adenocarcinoma, aiming to determine the recommended phase 2 dose and assess efficacy and safety.
Potential Benefits of Elraglusib: Previous studies have shown that elraglusib can enhance immune responses in cancer treatment, demonstrating significant improvements in overall survival rates when combined with other therapies, suggesting its potential as a novel approach in treating difficult cancers like pancreatic adenocarcinoma.
Actuate Therapeutics Announces Encouraging Phase II Results for Salivary Gland Cancers
Positive Study Results: Actuate Therapeutics reported favorable outcomes from a Phase II study of elraglusib combined with carboplatin or cisplatin for advanced metastatic salivary gland cancers, showing a median overall survival of 18.6 months.
Patient Demographics and Survival Rates: The study included 47% adenoid cystic carcinoma (ACC) and 53% non-ACC patients, with non-ACC patients experiencing a median overall survival of 27.8 months.
Progression-Free Survival: The median progression-free survival was 6.4 months, with only 27% of patients remaining progression-free at one year, contrasting with historical estimates for ACC and non-ACC.
Market Reaction: Following the announcement, Actuate shares increased by over 4% in pre-market trading, closing at $7.52, reflecting a 1.35% rise from the previous day.
HC Wainwright & Co. Affirms Buy Rating for Actuate Therapeutics, Keeps $20 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
Actuate Therapeutics Reveals Pricing for $15.0 Million Public Stock Offering
Public Offering Announcement: Actuate Therapeutics, Inc. has priced an underwritten public offering of 2,142,858 shares of common stock at $7.00 per share, aiming to raise approximately $15 million for working capital and corporate purposes.
Use of Proceeds: The company plans to utilize the net proceeds from the offering for general corporate needs, with the offering expected to close on September 11, 2025, pending customary closing conditions.
Company Focus: Actuate Therapeutics is a clinical-stage biopharmaceutical company developing therapies for challenging cancers, with its lead drug, elraglusib, targeting pathways that promote tumor growth and resistance to conventional treatments.
Forward-Looking Statements: The press release includes forward-looking statements regarding the offering's timing and completion, emphasizing the inherent risks and uncertainties that could affect actual results.
Actuate Therapeutics Analyst Starts Coverage Positively; Check Out Tuesday's Top 3 Initiations
Analyst Ratings Updates: Top Wall Street analysts have revised their outlooks on several companies, with a focus on upgrades and new coverage initiations.
Actuate Therapeutics Coverage: B. Riley Securities analyst Mayank Mamtani initiated coverage on Actuate Therapeutics (ACTU) with a Buy rating and a price target of $20, while the stock closed at $7.98.
Gyre Therapeutics Coverage: HC Wainwright & Co. analyst Matthew Keller also initiated coverage on Gyre Therapeutics (GYRE) with a Buy rating and a price target of $18, closing at $8.18.
CareDx Coverage: William Blair analyst Andrew Brackmann started coverage on CareDx (CDNA) with a Market Perform rating, with shares closing at $12.75.
B. Riley Securities Begins Coverage of Actuate Therapeutics with a Buy Rating and Sets Price Target at $20
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing strategies and intelligence.
Market Winning Tool: Traders utilize Benzinga Pro's resources to enhance their trading success in the stock market.
Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer
Clinical Trial Announcement: Actuate Therapeutics has initiated a Phase 1b clinical trial at UPMC Hillman Cancer Center to evaluate the combination of elraglusib, retifanlimab, and modified FOLFIRINOX as a frontline therapy for advanced pancreatic adenocarcinoma, aiming to determine the recommended phase 2 dose and assess efficacy and safety.
Potential Benefits of Elraglusib: Previous studies have shown that elraglusib can enhance immune responses in cancer treatment, demonstrating significant improvements in overall survival rates when combined with other therapies, suggesting its potential as a novel approach in treating difficult cancers like pancreatic adenocarcinoma.
